Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
Status:
Terminated
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
This was a non-randomized, open-label study of MK-1966 used in combination with SD-101 in the
treatment of advanced malignancies. The study included an initial Dose Evaluation phase (Part
A) to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) by
evaluating Dose Limiting Toxicities (DLTs) of four dose combinations of MK-1966 and SD-101.
Following determination of the MTD/MAD, approximately 20 participants each were to be
enrolled in two expansion cohorts (Parts B or C) to confirm/refine the MTD/MAD. The study was
terminated by the Sponsor before enrollment into Part A concluded and before enrollment into
Parts B and C began.